ArticleTranslational cancer research2025
The timing of surgery for elderly patients with locally advanced breast cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Older patients have poor tolerance to chemotherapy, and the timing of surgical treatment for elderly patients with locally advanced breast cancer is unclear. The objective of this study was to evaluate the long-term survival characteristics of elderly patients with locally advanced breast cancer and the timing of surgery. Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) database were used to explore the timing of surgery in locally advanced elderly breast cancer patients diagnosed between 2010 and 2015. The study population was 70 years of age or older and had a tumor-node-metastasis (TNM) stage of T3-4N0-3M0. Patients were divided into upfront surgery and neoadjuvant therapy (NAT). Overall survival (OS) was evaluated with Kaplan-Meier analysis (using the log-rank test) and multivariate Cox proportional hazards modeling. Survival outcomes were compared between the upfront surgery group and the neoadjuvant therapy group and subgroup comparisons of survival outcomes were performed. Propensity score matching (PSM) was used to match the variables between the two groups. Results: A total of 2,191 patients with locally advanced elderly breast cancer were included in this study. There were 1,498 patients in the upfront surgery group and 693 patients in the neoadjuvant therapy group. Age, tissue grade, stage, estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER-2) were independent risk factors for the prognosis of breast cancer-specific survival (BCSS) and OS (P values were less than 0.05). There were no statistically significant differences in BCSS (P=0.94) and OS (P=0.72) in the upfront surgery group compared to the NAT group. In the subgroup analysis of HER-2 positive breast cancer, OS (P=0.001) was higher in the neoadjuvant group than in the upfront surgery group. Conclusions: For locally advanced HER-2 positive elderly breast cancer, NAT can improve patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.